Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
1Hematology-Oncology Services, Santa Cabrini Hospital, and Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC.
Abstract:
Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) erlotinib and gefitinib were developed to target the epidermal growth factor receptor (egfr). Afatinib, an irreversible ErbB family blocker, was developed to block egfr (ErbB1), human epidermal growth factor receptor 2 (ErbB2), and ErbB4 signalling, and transphosphorylation of ErbB3. All of the foregoing agents are efficacious in treating nsclc, and their adverse event profile is different from that of chemotherapy. Two of the most common adverse events with egfr tkis are rash and diarrhea. Here, we focus on diarrhea. The key to successful management of diarrhea is to treat early and aggressively using patient education, diet, and antidiarrheal medications such as loperamide. We also present strategies for the effective assessment and management of egfr tki-induced diarrhea.
Insights
Managing diarrhea, a common side effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small-cell lung cancer, requires early and aggressive treatment with patient education, diet, and medication.
Area of Science:
- Oncology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) treatment is shifting towards personalized medicine.
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib are key targeted therapies.
- Afatinib, an irreversible ErbB family blocker, targets EGFR, ErbB2, and ErbB4.
Purpose of the Study:
- To focus on the management of diarrhea, a frequent adverse event associated with EGFR TKIs.
- To present strategies for the effective assessment and management of EGFR TKI-induced diarrhea.
Main Methods:
- Review of adverse event profiles of EGFR TKIs.
- Discussion of management strategies including patient education, dietary modifications, and antidiarrheal medications.
- Focus on early and aggressive treatment protocols.
Main Results:
- EGFR TKIs have different adverse event profiles compared to traditional chemotherapy.
- Rash and diarrhea are common adverse events of EGFR TKIs.
- Early and aggressive management is crucial for controlling EGFR TKI-induced diarrhea.
Conclusions:
- Effective management of EGFR TKI-induced diarrhea involves a multi-faceted approach.
- Patient education, dietary adjustments, and prompt use of antidiarrheal agents like loperamide are essential.
- Successful management can improve patient adherence and treatment outcomes in NSCLC.
More Related Videos
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...